@article{ref1,
title="Trends in carisoprodol abuse and misuse after regulatory scheduling: a retrospective review of California poison control calls from 2008 to 2015",
journal="Clinical toxicology (Philadelphia, Pa.)",
year="2018",
author="Sun, Christie and Hollenbach, Kathryn A. and Cantrell, F. L.",
volume="56",
number="7",
pages="653-655",
abstract="BACKGROUND: In January 2012, carisoprodol was classified as a Schedule IV substance under the controlled substances act from a previously non-controlled, non-scheduled classification. Carisoprodol is marketed as a skeletal muscle relaxant and is commonly cited for its abuse potential. <br><br>OBJECTIVES: We aimed to compare volume of calls involving carisoprodol abuse or misuse to a statewide poison control system before and after the scheduling change. <br><br>METHODS: Data were extracted from poison control calls coded as &quot;misuse/abuse&quot; involving carisoprodol from four years before (2008 to 2011) and four years after (2012 to 2015) the scheduling change. The volume of calls from pre- and post-scheduling change was compared after adjusting for yearly California census data. <br><br>RESULTS: The number of calls related to carisoprodol abuse or misuse was significantly decreased in the four years following the change compared to the four years before. <br><br>CONCLUSION: Scheduling of carisoprodol was temporally related to decreased exposures as reported to California Poison Control Centers. Governmental regulation may impact a drug's potential for abuse.<p /> <p>Language: en</p>",
language="en",
issn="1556-3650",
doi="10.1080/15563650.2017.1414950",
url="http://dx.doi.org/10.1080/15563650.2017.1414950"
}